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Abstract 
Electromagnetic therapy is a non‑invasive and safe approach for the management of several pathological conditions 
including neurodegenerative diseases. Parkinson’s disease is a neurodegenerative pathology caused by abnormal 
degeneration of dopaminergic neurons in the ventral tegmental area and substantia nigra pars compacta in the 
midbrain resulting in damage to the basal ganglia. Electromagnetic therapy has been extensively used in the clinical 
setting in the form of transcranial magnetic stimulation, repetitive transcranial magnetic stimulation, high‑frequency 
transcranial magnetic stimulation and pulsed electromagnetic field therapy which can also be used in the domestic 
setting. In this review, we discuss the mechanisms and therapeutic applications of electromagnetic therapy to allevi‑
ate motor and non‑motor deficits that characterize Parkinson’s disease.
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Background
Parkinson’s disease
Parkinson’s disease (PD) is one of the most common 
neurodegenerative diseases worldwide, second only to 
Alzheimer’s disease (AD) [1]. PD is accompanied by the 
impairment of the cortico-subcortical excitation and 
inhibition systems, hence belonging to the involuntary 
movement diseases [2]. PD is caused by progressive loss 
of structure and function of dopaminergic neurons in the 
ventral tegmental area and substantia nigra pars com-
pacta in the midbrain with subsequent damage to the 
basal ganglia (BG) [3]. Cumulative evidence supports 
the hypothesis that PD is the result of complex interac-
tions among genetic abnormalities, environmental toxins 
and mitochondrial dysfunction [4–6]. The mechanisms 
of neuronal degeneration characterizing PD have been 
studied extensively and include a complex interplay 
among multiple pathogenic processes including oxidative 
stress, protein aggregation, excitotoxicity and impaired 
axonal transport [7]. The increasing number of genes 
and proteins critical in PD is unraveling a complex net-
work of molecular pathways involved in its etiology, sug-
gesting that common mechanisms underlie familial and 
sporadic PD, the two forms of this pathology. While 
the sporadic form is the most common (90–95% of PD 
cases), only 5–10% of PD cases are familial [8, 9]. At least 
ten distinct loci are responsible for rare Mendelian forms 
of PD and mutations in five genes have been linked to 
familial PD [10]. PD is characterized by motor and non-
motor symptoms. The main motor symptoms include 
bradykinesia, tremor at rest (tremor affecting the body 
part that is relaxed or supported against gravity and not 
involved in purposeful activities [11]), rigidity and pos-
tural instability [12–17]. However, motor symptoms are 
now considered as the “tip of the iceberg” of PD clinical 
manifestations. PD non-motor symptoms include cogni-
tive decline, decrease in sleep efficiency, increased wake 
after sleep onset, sleep fragmentation, and vivid dreams 
as well as neuropsychiatric symptoms such as depression 
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and psychosis, [18–23]. Pain syndrome and autonomic 
dysfunctions have also been observed in PD patients 
[24–26].
Neuroimaging and genes: towards a personalized 
medicine for Parkinson’s disease
Several research groups have begun to perform genome-
wide association studies (GWAS) on data or index 
measures derived from brain images, with the final 
goal of finding new genetic variants that might account 
for abnormal variations in brain structure and func-
tion that increase the risk of a given disease. Numerous 
genes have been identified using GWAS and have been 
associated with PD. They include alpha-synuclein, vacu-
olar protein sorting-associated protein 35, human leu-
kocyte antigen family, leucine-rich repeat kinase 2 and 
acid β-glucosidase [27–29]. Neuroimaging associates 
individual differences in the human genome to structural 
and functional variations into the brain. Van der Vegt and 
colleagues reported structural and functional brain map-
ping studies that have been performed in individuals car-
rying a mutation in specific PD genes including PARK1, 
PARK2, PARK6, PARK7, PARK8, and discussed how this 
“neurogenetics-neuroimaging approach” provides unique 
means to study key PD pathophysiological aspects [30]. 
In addition, neuroimaging of presymptomatic (non-man-
ifesting) mutation carriers has emerged as a valuable tool 
to identify mechanisms of adaptive motor reorganiza-
tion at the preclinical stage that may prevent or delay PD 
clinical manifestation [30]. Neuroimaging may be useful 
to study the effectiveness of electromagnetic therapy in 
PD patients.
Available therapies for Parkinson’s disease
PD treatment includes the use of pharmacological agents 
such as the dopaminergic agent l-3,4-dihy-droxy-phe-
nylalanine (Levodopa or l-dopa) and stereotactic brain 
surgery which are associated with numerous side effects 
[31]. For example, the on-and-off phenomenon includes 
profound diurnal fluctuations in the psychomotor state 
of PD patients treated with l-dopa [32]. Furthermore, 
l-dopa loses effectiveness over time and can induce 
motor fluctuations such as the “wearing off” effect and 
dyskinesia [33]. While l-dopa metabolites are neurotoxic 
[33], the search for alternate, non-dopaminergic thera-
pies to overcome the l-dopa-induced side effects has 
positioned adenosine A2A receptor (A2AR) antagonists 
as a promising therapeutic option for PD treatment [34]. 
Despite the favorable features of A2AR antagonists, their 
pharmacological properties, such as poor oral bioavail-
ability and the lack of blood–brain barrier permeability, 
constitute a major problem to their clinical application 
[35]. Furthermore, regular physiotherapy and instrumen-
tal rehabilitation that have been employed to manage 
PD symptoms, such as tremor, slowness and difficulty in 
walking, are only moderately helpful [36]. Electromag-
netic therapy has also been extensively used for PD treat-
ment and may represent a promising therapeutic option 
for this condition since it promotes a lasting improve-
ment in motor and non-motor symptoms [37–41].
Electromagnetic therapy background
Electromagnetic therapy includes the use of six groups 
of electromagnetic fields as previously described [42, 43] 
and summarized below:
  • Static/permanent magnetic fields can be created by 
various permanent magnets as well as by passing 
direct current through a coil.
  • Transcranial magnetic stimulation (TMS) utilizes 
frequencies in the range 1–200 Hz.
  • Low-frequency electromagnetic fields mostly utilize 
60 Hz (in the US and Canada) and 50 Hz (in Europe 
and Asia) frequencies in distribution lines.
  • Pulsed radiofrequency fields utilize frequencies in the 
range 12–42 MHz.
  • Millimeter waves refer to very high-frequency in the 
range 30–100 GHz.
 • Pulsed electromagnetic fields (PEMFs) utilize fre-
quencies in the range 5–300  Hz with very specific 
shapes and amplitudes.
Electromagnetic therapy is defined as the use of time-
varying electromagnetic fields of low-frequency values 
(3  Hz–3  kHz) that can induce a sufficiently strong cur-
rent to stimulate living tissue [44]. Electromagnetic fields 
can penetrate all tissues including the epidermis, dermis, 
and subcutaneous tissue, as well as tendons, muscles and 
bones [45]. The amount of electromagnetic energy used 
and its effect on the target organ depends on the size, 
strength and duration of treatment [44]. Electromag-
netic fields can be divided into two categories: static and 
time-varying. Electromagnetic therapy falls into two cat-
egories: (1) hospital use which includes TMS, repetitive 
transcranial magnetic stimulation (rTMS) and high-fre-
quency TMS and (2) home use including PEMF therapy.
Aim and searching criteria
We searched Pubmed/Medline using the keywords “Par-
kinson’s Disease” combined with “electromagnetic ther-
apy”, “TMS”, “rTMS”, “high-frequency TMS” or “PEMF” 
and we included articles published between 1971 and 
2015. This article aims to review the state of the art of 
electromagnetic therapy for treatment of PD.
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Transcranial magnetic stimulation
TMS is a safe and non-invasive method of electrical stim-
ulation of neurons in the human cerebral cortex, modi-
fying neuronal activity locally and at distant sites when 
delivered in series of pulses [46]. TMS is also a useful tool 
to investigate various aspects of human neurophysiology, 
particularly corticospinal function, in health and disease 
[47]. An electromagnetic field generator sends a current 
with a peak amplitude of about 8,000 A that lasts about 
1 ms, through an induction coil placed on the scalp [48]. 
TMS is based on the principle of electromagnetic induc-
tion, as discovered by Faraday in 1838. The current flow-
ing briefly in the iron coil placed over a patient’s head 
generates an electromagnetic field that penetrates the 
scalp and skull reaching the brain where it induces a sec-
ondary ionic current. The site of stimulation of the brain 
is the point along its length at which sufficient current 
passes through its membrane to cause depolarization 
[49]. TMS can be used to determine several parameters 
associated to different aspects of cortical excitability: 
(1) the resting motor threshold or active motor thresh-
old which reflects membrane properties; (2) the silent 
period, which is a quiescent phase in the electromyogram 
(EMG), is partially of cortical origin and is related to the 
function of gamma-aminobutyric acid receptors; (3) the 
short intracortical inhibition and facilitation which occur 
when a subthreshold stimulus precedes a suprathreshold 
stimulus by less than 5 ms or 8–30 ms, respectively. The 
peak of electromagnetic field strength is related to the 
magnitude of the current and the number of turns of wire 
in the coil [50]. The electrical current is rapidly turned 
on and off in the coil through the discharge of electronic 
components called the capacitors.
Transcranial magnetic stimulation in Parkinson’s disease
TMS clinical applications were first reported by Barker 
and colleagues who stimulated the brain, spinal cord 
and peripheral nerves using TMS with low or no pain 
[51]. Following this work, several TMS protocols that 
evidenced the correlation of TMS with peripheral EMG 
and monitored the modulation of TMS-induced motor 
evoked potentials (MEPs), were described [52–54]. For 
example, Cantello and coworkers studied the EMG 
potentials evoked in the bilateral first dorsal interosseus 
muscle by electromagnetic stimulation of the cortico-
motoneuronal descending system in 10 idiopathic PD 
patients without tremor but with  rigidity with asym-
metric body involvement and 10 healthy controls [55]. 
The threshold to cortical stimulation measured on the 
rigid side of PD patients was lower than on  the con-
tralateral side or than normal values. PD patients’ MEPs 
on the rigid side were larger compared to controls when 
the cortical stimulus was at rest or during slight tonic 
contraction of the target muscle [55]. Several clinical tri-
als have pointed out the therapeutic efficacy of TMS in 
PD patients [3, 31, 56, 57]. For example, biomagnetic 
measurements performed using magnetoencephalog-
raphy (MEG) in 30 patients affected by idiopathic PD 
exposed to TMS evidenced that 60% of patients did not 
exhibit tremor, muscular ache or dyskinesias for at least 
1 year after TMS therapy [58]. The patients’ responses to 
TMS included a feeling of relaxation, partial or complete 
disappearance of muscular ache and l-dopa-induced dys-
kinesias as well as rapid reversal of visuospatial impair-
ment [58]. Additional MEG measurements in PD patients 
also showed abnormal brain functions including slowing 
of background activity (increased theta and decreased 
beta waves) and increased alpha band connectivity [59]. 
These changes may reflect abnormalities in specific net-
works and neurotransmitter systems, and could be useful 
for differential diagnosis and treatment monitoring.
Repetitive transcranial magnetic stimulation
rTMS is a non-invasive technique of brain stimulation 
based on electromagnetic induction [60]. rTMS has the 
potential to alter cortical excitability depending on the 
duration and mode of stimulation [61]. The electromag-
netic pulse easily passes through the skull, and causes 
small electrical currents that stimulate nerve cells in the 
targeted brain region [62]. Since this type of pulse gener-
ally does not reach further than two inches into the brain, 
it is possible to selectively target specific brain areas [62]. 
Generally, the patient feels a slight knocking or tapping 
on the head as the pulses are administered. rTMS fre-
quencies of around 1  Hz induce an inhibitory effect on 
cortical excitability [63] and stimulus rates of more than 
5 Hz generate a short-term increase in cortical excitabil-
ity [64]. rTMS induces a MEP of the muscles of the lower 
extremities by stimulating the motor and supplementary 
motor area (SMA) of the cerebral cortex [31].
Repetitive transcranial magnetic stimulation in Parkinson’s 
disease
Several studies have reported the efficacy of rTMS on 
PD motor symptoms [65–69]. These effects are primarily 
directed at surface cortical regions, since the dopamin-
ergic deficiency in PD is localized to the subcortical BG. 
The BG comprises a group of interconnected deep brain 
nuclei, i.e. the caudate and putamen, globus pallidus, sub-
stantia nigra and the subthalamic nucleus (STN) that, 
through their connections with the thalamus and the 
cortex, primarily influence the involuntary components 
of movement and muscle tone [70]. Several studies have 
documented the long-term effects of rTMS applied to 
PD patients for several days, rather than single sessions 
[71–73]. For instance, Shimamoto and coworkers applied 
Page 4 of 12Vadalà et al. Behav Brain Funct  (2015) 11:26 
rTMS on a broad area including the left and right motor, 
premotor and SMAs in nine PD patients for a period of 
2  months, and observed improvements in the Unified 
Parkinson’s Disease Rating Scale (UPDRS), a rating scale 
used to follow PD progression [74]. A further trial in PD 
patients reported a shortened interruption of voluntary 
muscle contraction, defined cortical silent period, sug-
gesting a disturbed inhibitory mechanism in the motor 
cortex [57]. PD patients show altered activation pat-
terns in the SMA and overall less cortico-cortical excit-
ability [75–81] that play a key role in motor selection in 
sequentially structured tasks, including handwriting. In 
a randomized controlled trial with a crossover design in 
PD patients, rTMS applied over the SMA influenced sev-
eral key aspects of handwriting, e.g. vertical size and axial 
pressure, at least in the short term [82]. Ten PD patients 
treated with rTMS, evidenced short-term changes in 
functional fine motor task performance. rTMS over 
the SMA compensated for cortico-striatal imbalance 
and enhanced cortico-cortical connections. This treat-
ment improved PD patients deficits such as reduction in 
speed during the writing task and decrease in letter size 
(micrographia).
Two mechanisms have been proposed to explain how 
cortically directed rTMS may improve PD symptoms: 
(1) rTMS induces brain network changes and positively 
affects the BG function; (2) rTMS directed to cortical 
sites compensates for PD-associated abnormal changes 
in cortical function [60]. Indeed, in support of the former 
mechanism, rTMS might modulate cortical areas, such 
as the prefrontal cortex and primary motor cortex, which 
are substantially connected to both the striatum and STN 
via glutamatergic projection, and thus indirectly modu-
late the release of dopamine in the BG [83]. Several TMS/
functional imaging studies have demonstrated the effects 
of rTMS on BG and an increase in dopamine in the BG 
after rTMS applied to the frontal lobe [84].
rTMS can also transiently disrupt the function of a 
cortical target creating a temporary “virtual brain lesion” 
[85–87]. Mottaghy and coworkers have studied the abil-
ity of rTMS to produce temporary functional lesions in 
the BG, an area involved in working memory, and cor-
related these behavioral effects with changes in regional 
cerebral blood flow in the involved neuronal network 
[88]. Functional imaging and TMS studies in PD subjects 
have shown altered cortical physiology in areas associ-
ated to the BG such as the SMA, dorsolateral prefrontal 
cortex and primary motor cortex [57, 89], characterized 
by excessive corticospinal output at rest, concomitant to, 
or resulting from a reduced intracortical inhibition [60]. 
These altered changes in cortical function in PD patients 
might avoid the suppression of competing motor areas 
and therefore decrease the motor system performance, 
resulting in symptoms such as tonic contractions and 
rigidity [89].
rTMS has not only been applied to a motor area of the 
brain but has also been used to target PD non-motor 
deficits. For example, in a study involving six PD patients 
with mild cognitive impairment, a cognitive dysfunction 
defined by deficits in memory, rTMS was delivered over 
the frontal region at 1.2 times the motor threshold (mini-
mum stimulation intensity) of the right abductor pollicis 
brevis muscle [3]. Over a period of 3 months, rTMS was 
performed for a total of 1200 stimulations. Improvement 
in neuropsychological tests (the trail-making test part 
B and the Wisconsin card-sorting test) was observed in 
all patients. In addition, an improvement in subjective 
symptoms and objective findings were also observed 
by the subjects, their families, and the therapists. The 
changes observed in PD subjects included “faster reac-
tions”, “better body movement and smoother standing-
up and movement”, “more active”, “more cheerful”, and 
“more expressive”. An increase in the amount of conver-
sation, an increase in the neural mechanisms of mutual 
understanding within daily living and an improvement 
in responses to visitors were also noted, if compared to 
baseline. Additionally, changes such as better hand usage 
while eating and better sleep were also observed.
Cognitive dysfunction is often seen in PD patients with 
major depression and its neural basis could be the func-
tional failure of the frontostriatal circuit [3, 90]. Ten days 
of rTMS in the frontal cortex can effectively alleviate PD-
associated depression as shown by an open trial report-
ing a significant decrease in the Hamilton Depression 
Rating Scale (HDRS) scores [91]. A further double blind, 
sham stimulation-controlled, randomized study, involv-
ing 42 idiopathic PD patients affected by major or minor 
depression undergoing rTMS for 10  days, evidenced a 
mean decrease in HDRS and Beck depression inventory 
after therapy [92].
In opposition to the above mentioned positive reports 
concerning the efficacy of rTMS in PD patients, a lack of 
effectiveness of rTMS on objective or subjective symp-
toms has also been described. For example, in a study 
involving 85 idiopathic PD patients, no significant differ-
ences in clinical features were observed between patients 
receiving rTMS and sham stimulation [65]. Moreover, 
total and motor score of UPDRS were improved by rTMS 
and sham stimulation in the same manner. Despite this 
improvement, PD patients treated with rTMS revealed 
signs of depression, reporting no subjective benefits. In 
another randomized crossover study, 10 patients affected 
by idiopathic PD received rTMS to the SMA which 
resulted in subclinical worsening of complex and pre-
paratory movement [93]. The rTMS protocol was not 
tolerated by 2 out of 10 patients. Furthermore, this study 
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showed that, following rTMS, subtle regional disruption 
can persist for over 30  min, raising safety concerns. A 
further randomized crossover study involving 11 patients 
with idiopathic PD, treated with rTMS over the motor 
cortex, did not show any therapeutic effect on concurrent 
fine movement in PD [94].
In summary, conflicting findings regarding the effi-
cacy of rTMS in PD have been reported and they can 
be explained by differences in stimulation parameters, 
including intensity, frequency, total number of pulses, 
stimulation site and total number of sessions. There-
fore, further studies comparing different parameters are 
required.
High‑frequency transcranial magnetic stimulation
High-frequency TMS consists of continuous high-fre-
quency stimulation of specific brain regions, including 
the motor cortex, cerebellum and BG, through implanted 
large four-contact electrodes connected to a pulse gen-
erator and positioned into the center of the target region 
[70]. Such stimulation induces an electrical field that 
spreads and depolarizes neighboring membranes of cell 
bodies, afferent and efferent axons, depending on neu-
ronal element orientation and position in the field and 
on stimulation parameters [95]. Optimal clinical results 
are obtained by using pulses of 60–200 ms duration and 
1–5  V amplitude, delivered in the STN at 120–180  Hz 
[96]. For example, high-frequency TMS produces a tran-
sient blockade of spontaneous STN activity, defined 
HFS-induced silence. During HFS-induced silence, the 
persistent Na+ current is totally blocked and the Ca2+-
mediated responses are strongly reduced, suggesting that 
T- and L-type Ca2+ currents are transiently depressed by 
high-frequency TMS [97].
Indeed, recent evidence suggests that the stimulation 
of the motor cortex, the cerebellum and the BG not only 
produces inhibitory and excitatory effects on local neu-
rons, but also influences afferent and efferent pathways. 
Therefore, the mechanism of action of high-frequency 
TMS depends on changes in neural activity generated in 
the stimulated, afferent and efferent nuclei of the BG and 
motor cortex [98].
High‑frequency transcranial magnetic stimulation 
in Parkinson’s disease
In the first PD patients treated with high-frequency TMS 
in 1993, motor symptoms, tremor, rigidity and akinesia 
improved significantly allowing to decrease the admin-
istration of l-dopa by a mean of 55% [99]. Since then, 
several thousands of patients worldwide have been fitted 
with high-frequency TMS implants achieving marked 
improvements in their symptoms, making this method 
the reference procedure for advanced PD [100]. The time 
course of improvement following high-frequency TMS 
treatment differs for different cardinal symptoms of PD 
[101]. For instance, rigidity and resting tremor decrease 
immediately, within a few seconds after high-frequency 
TMS [102]. Different clinical effects are observed in PD 
patients depending on the site of stimulation [103]. For 
example, stimulation of the ventral intermediate nucleus 
of the thalamus can dramatically relieve PD-associated 
tremor [104]. Similarly, stimulation of the STN or globus 
pallidus interna (GPi) can substantially reduce rigidity, 
tremor, and gait difficulties in patients affected by idi-
opathic PD [105]. Stimulation of the GPi also reduces 
all of the major PD motor manifestations, including the 
reduction of l-dopa-induced dyskinesias and involun-
tary movements produced by individual doses of dopa-
minergic medications that can limit treatment efficacy 
[106]. Thalamic stimulation in the region of the ventral 
intermediate nucleus reduces limb tremor but it has lit-
tle effect on other manifestations of the disease [107]. In 
order to explain the beneficial effects of high-frequency 
TMS, two fundamental mechanisms have been proposed 
by Garcia and coworkers: silencing and excitation of STN 
neurons [95]. They reported that high-frequency TMS 
using stimulus parameters that yield therapeutic effects 
has a dual effect, i.e. it suppresses spontaneous activity 
and drives STN neuronal activity. High-frequency TMS 
switches off a pathological disrupted activity in the STN 
(i.e. silencing of STN neurons mechanism) and imposes 
a new type of discharge in the upper gamma-band fre-
quency (60–80 Hz range) that is endowed with beneficial 
effects (i.e. excitation of STN neurons mechanism) [95]. 
This improvement generated by high-frequency TMS 
is due to parallel non-exclusive actions, i.e. silencing of 
ongoing activity and generation of an activity pattern in 
the gamma range [108]. There is an important advantage 
in silencing spontaneous activity and generating a pat-
tern: the signal to noise ratio and the functional signifi-
cance of the new signal are enhanced [109].
Techniques and preparations employed to study the 
mechanisms of high-frequency TMS include electrophys-
iological techniques, measurement of neurotransmit-
ter release in vivo, post-mortem immunohistochemistry 
of a metabolic marker such as cytochrome oxidase and 
imaging studies in  vivo [95]. Such results consistently 
show a post-stimulus period of reduced neuronal firing 
followed by the slow recovery of spontaneous activity. 
High-frequency TMS, at frequencies >50 Hz, applied to 
the STN of PD patients undergoing functional stereotac-
tic procedures [110–112], to the STN of rats in vivo [113, 
114] and rat STN slices in vitro [97, 115, 116], produces 
a period of neuronal silence of hundreds of milliseconds 
to tens of seconds. During brief high-frequency TMS 
in PD patients off medication and in the murine model 
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of parkinsonism obtained by acute injections of neuro-
toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for 
5 consecutive days, a reduced STN activity, as response 
to stimulation, is observed at 5–14 Hz and this response 
is frequency-dependent [114]. High-frequency TMS has 
two main advantages: (a) it reduces the time a patient 
spends in the “off” state because the individual dose of 
these profound diurnal fluctuations leaves a person slow, 
shaky, stiff, and unable to rise from a chair; (b) it allows 
the reduction of medications and their consequent side 
effects [117].
Pulsed electromagnetic field therapy
PEMF therapy is a non-static energy delivery system, char-
acterized by electromagnetic fields inducing microcurrents 
in the target body tissues [118]. These microcurrents elicit 
specific biological responses depending on field param-
eters such as intensity, frequency and waveform [119]. The 
benefits of PEMF therapy have been observed in several 
clinical studies for treatment of several medical conditions 
including knee osteoarthritis [120], shoulder impingement 
syndrome [121], lower back pain [122, 123], multiple scle-
rosis [124, 125], cancer [121, 123, 125, 126], PD [127], AD 
[128] and reflex sympathetic dystrophy syndrome [129]. 
A large number of PEMF therapy devices contains user-
friendly software packages with pre-recorded programs 
with the ability to modify programs depending on the 
patient’s needs [43, 130–132]. Examples of PEMF devices 
are the Curatron® (Amjo Corp, West Chester, PA, USA), 
Seqex® system (S.I.S.T.E.M.I. Srl, Trento, Italy), MRS 
2000®, iMRS®, QRS® (all produced by Swiss Bionic Solu-
tions Schweiz GmbH, Dulliken, Switzerland) and TESLA 
Stym (Iskra Medical, Ljubljana, Slovenia).
Pulsed electromagnetic field therapy in Parkinson’s disease
In October 2008 the Food and Drug Administration 
approved the use of PEMF therapy for treatment of 
major depressive disorder in PD patients who failed to 
achieve satisfactory improvement from very high dos-
ages of antidepressant medications [133, 134]. Several 
studies reported PEMF therapy improved cognitive 
functions and motor symptoms. For example, an inves-
tigation involving three elderly PD patients with cogni-
tive impairment assessed the effect of PEMF therapy 
on macrosomatognosia, a disorder of the body image in 
which the patient perceives a part or parts of his body 
as disproportionately large [135]. After receiving PEMF 
therapy, PD patients’ drawings showed reversal of mac-
rosomatognosia (assessed by Draw-a-Person test) with 
reduction of the right parietal lobe dysfunction. Further-
more, PEMF therapy applied to a 49-year-old male PD 
patient with stage 3 disease, as assessed by Hoehn and 
Yahr scale, resulted in a marked improvement in motor 
and non-motor symptoms such as mood swings, sleep-
lessness, pain and sexual and cognitive dysfunctions, 
suggesting that PEMF therapy should be tested in large 
cohorts of PD patients as monotherapy and should also 
be considered as a treatment modality for de novo diag-
nosed PD patients [136]. PEMF therapy was also effec-
tive in improving visuospatial deficits in four PD patients, 
as assessed by the clock-drawing test [137]. Moreover, 
PEMF therapy improved PD-associated freezing (a symp-
tom manifesting as a sudden attack of immobility usually 
experienced during walking) in 3 PD patients through the 
facilitation of serotonin neurotransmission at both junc-
tional and non-junctional neuronal target sites [127].
Discussion
Although many studies on electromagnetic therapy 
included only a small number of participants, several 
investigations suggest that this therapy is effective in 
treating PD patients’ motor and non-motor symptoms. 
In the development of electromagnetic therapies, it is 
important to clarify the pathophysiological mechanisms 
underlying the symptoms to treat in order to determine 
the appropriate brain region to target. Thus, in the future, 
electromagnetic therapy must tend towards a more per-
sonalized approach, tailored to the specific PD patient’s 
symptoms. All the types of electromagnetic therapy 
described in this review can be used in combination with 
pharmacological and non-pharmacological therapies but 
this approach is understudied in PD patients. Therefore, 
specific protocols should be designed and tested in com-
bination with other therapies in future controlled trials in 
patients affected by PD.
Transcranial magnetic stimulation
TMS increases the release of dopamine in the striatum 
and frontal cortex, which in turn improves PD symp-
toms including motor performance [138]. Further-
more, TMS applied in the prefrontal cortex induces 
the release of endogenous dopamine in the ipsilat-
eral caudate nucleus as observed by positron emis-
sion tomography in healthy human subjects [89]. TMS 
application results in partial or complete disappear-
ance of muscular pain and l-dopa-induced dyskinesia 
as well as regression of visuospatial impairment. This 
clinical improvement is followed by MEG improve-
ment and normalization recorded after TMS, suggest-
ing that TMS has an immediate and beneficial effect on 
corticostriatal interactions that play an important role 
in the pathophysiology of PD [58]. Cerasa and cowork-
ers observed that repetitive TMS applied over the infe-
rior frontal cortex reduced the amount of dyskinesia 
induced by a supramaximal single dose of levodopa in 
PD patients, suggesting that this area may play a key 
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role in controlling the development of dyskinesia [139]. 
The mechanism underlying TMS effectiveness in PD 
remains an unanswered question due to the complex-
ity of behavioral and neuroendocrine effects exerted by 
the TMS when applied to biological systems and their 
potential impact on neurotransmitter functions [140]. 
The effect of TMS differs depending on the stage of the 
disease, the age of disease onset, the amount of cer-
ebral atrophy and genetic factors [37]. TMS has a low 
cost and is simple to operate and portable, opening the 
possibility for patients to perform at home stimulation 
which could be of high relevance in the elderly and in 
patients who are severely disabled. As far as side effects 
are concerned, the muscles of the scalp, jaw or face 
may contract or tingle during the procedure and mild 
headache or brief lightheadedness may occur [141, 
142]. A recent large-scale study on the safety of TMS 
found that most side effects, such as headaches or scalp 
discomfort, were mild or moderate, and no seizures 
occurred [143]. Although evidence shows that TMS 
exerts complex cellular, systemic and neuroendocrine 
effects on biological systems impacting neurotransmit-
ter functions [58], future controlled studies in larger 
cohorts of patients and with a long term follow-up are 
needed to further clarify the mechanisms underlying 
TMS efficacy in PD patients.
Repetitive transcranial magnetic stimulation
rTMS can be defined as a safe and non-invasive tech-
nique of brain stimulation which allows to specifically 
treat PD with low-frequency electromagnetic pulses [60]. 
As opposed to high-frequency TMS, which can induce 
convulsions in healthy subjects, rTMS does not affect 
the electroencephalogram pattern [71, 144]. Slow waves 
have been induced by rTMS over the right prefrontal 
area, a brain area involved in executive dysfunction that 
is observed in early stages of PD and is characterized by 
deficits in internal control of attention, set shifting, plan-
ning, inhibitory control, dual task performance, decision-
making and social cognition tasks [3, 145]. rTMS applied 
to PD patients, enhances not only executive function, but 
also motor function, subjective symptoms and objective 
findings [3]. rTMS also increases cognitive function and 
other symptoms associated to the prefrontal area in PD 
patients [146]. In PD patients, therapeutic efficacy and 
long-term benefits of rTMS are obtained following mul-
tiple regular sessions rather than single sessions, but side 
effects associated to this therapy still warrant investiga-
tion in large controlled trials.
High‑frequency magnetic stimulation
The observations that STN activity is disorganized in PD 
patients and that a lesion or chemical inactivation of STN 
neurons ameliorate motor symptoms led to the hypoth-
esis that high-frequency TMS silences STN neurons 
and, by eliminating a pathological pattern, alleviates PD 
symptoms [147–151]. Garcia and colleagues proposed 
another hypothesis suggesting that high-frequency TMS 
suppresses not only the pathological STN activity but also 
imposes a new activity on STN neurons [95]. They pro-
posed that high-frequency TMS excites the stimulated 
structure and evokes a regular pattern time-locked to the 
stimulation, overriding the pathological STN activity. As 
a consequence, high-frequency TMS removes the STN 
spontaneous activity and introduces a new and regular 
pattern that improves the dopamine-deficient network 
[95]. Elahi and coworkers found that high-frequency TMS 
modulates the excitability of the targeted brain regions 
and produces clinically significant motor improvement in 
PD patients [66]. This improvement is due to parallel non-
exclusive actions, i.e. silencing of ongoing activity and 
generation of an activity pattern in the high gamma range 
[152]. Several clinical studies reported positive clinical 
results following high-frequency TMS in l-dopa-respon-
sive forms of PD, including patients with selective brain 
dopaminergic lesions [153]. It remains unclear whether 
the mechanisms of action of high-frequency TMS and 
l-dopa are similar or they could be even synergic. How-
ever, high-frequency TMS improves the l-dopa-sensitive 
cardinal motor symptoms of PD patients with benefits 
similar to those given by l-dopa, though with reduced 
motor complications [154, 155]. The interactions with 
the dopaminergic system seem to be a key factor explain-
ing the efficacy of both treatments [156]. High-frequency 
TMS changes dopamine lesion-induced functional altera-
tions in the BG of PD animal models and gives an insight 
into the mechanisms underlying its antiparkinsonian 
effects [114, 157, 158]. The intrinsic capacity of the BG 
to generate oscillations and change rapidly from a physi-
ological to a pathogenic pattern is crucial; the next step 
will be to identify how high-frequency TMS is propagated 
inside the BG. Disadvantages of this therapy are the high 
cost and limited availability of the devices to specialized 
medical centers, limited knowledge of potential long-term 
side effects and the necessity to employ highly trained 
personnel.
Pulsed electromagnetic fields
PEMF therapy improves PD symptoms including tremor, 
slowness of movement and difficulty in walking [159]. 
It is non-invasive, safe and improves PD patients’ qual-
ity of life [124, 160]. PEMF therapy, employed for PD 
treatment, supports the body’s own healing process for 
4–6 h after therapy session [161–163]. It can be used at 
home and applied to the entire body or locally to target 
a specific body area and, if compared with dopaminergic 
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systemic therapy, e.g. l-dopa, it can offer an alternative 
treatment avoiding systemic side effects such as hepato-
toxicity and nephrotoxicity.
Conclusions
Electromagnetic therapy opens a new avenue for PD treat-
ment. Each electromagnetic therapy technique described 
in this review can be applied according to a single proto-
col or as a combination of different protocols specifically 
tailored to the PD patient’s needs. Beyond the necessity 
to choose coil or electrode size and placement, there is a 
variety of parameters that have to be taken into account 
when designing electromagnetic therapy approaches and 
they include stimulation intensity, duration, frequency, 
pattern, electrode polarity and size. Furthermore, electro-
magnetic therapy can also be combined with pharmaco-
logical or non-pharmacological treatments, e.g. physical 
therapy and cognitive tasks, to produce additive or poten-
tiated clinical effects. In conclusion, electromagnetic 
therapy represents a non-invasive, safe and promising 
approach that can be used alone or combined with con-
ventional therapies for the challenging treatment of PD 
motor and non-motor symptoms.
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